Findings confirmed advanced TNBC patients with PD-L1 10 or above benefit from Keytruda, but other data show PD-L1 doesn't predict benefit in earlier-stage TNBC.
The study showed that metastatic breast cancer patients are more likely to benefit from precision cancer drugs matched based on biomarkers with strong actionability evidence.
The Phase III DREAMseq trial pinpointed these patients' best treatment sequence, but questions linger about anti-PD-1 monotherapy and emerging treatments.
Geneseeq collaborated with researchers in China to generate three molecularly defined subgroups to guide adjuvant NSCLC treatment with either TKIs or chemotherapy.
Using this approach as a "shortcut" to matching patients to drugs has shown a clear survival benefit, raising both commercial interest and logistical concerns.
Agencies and drugmakers are struggling to generate consistent standards and regulatory criteria for evaluating autologous cell therapies.
A recent study showed that the firm's technology could predict glioblastoma patients' chemo responses as well or better than an established genomic biomarker.
A multiomic study out of TGen and the Beat Childhood Cancer Research Consortium found potentially actionable tumor changes at the point of disease relapse.
The percentage of NSCLC patients undergoing biomarker testing has increased in recent years, but turnaround time and socioeconomic disparities need addressing.
Oncologists argued for and against comprehensive NGS at the point of diagnosis but agreed on the need to address quality and cost barriers first.